KRAS and non-small cell lung carcinoma: On the basis of these results and previous reports,21,22 we concluded that trametinib-induced short-term proliferation inhibition in KRAS-mutant NSCLC cells was attributed mainly to the inhibition of the MEK-ERK pathway.